Grifols (NASDAQ:GRFS) Shares Gap Up - What's Next?

Grifols, S.A. (NASDAQ:GRFS - Get Free Report)'s stock price gapped up before the market opened on Wednesday . The stock had previously closed at $9.00, but opened at $9.44. Grifols shares last traded at $9.62, with a volume of 483,885 shares changing hands.

Wall Street Analysts Forecast Growth

GRFS has been the topic of several recent analyst reports. JPMorgan Chase & Co. raised their price objective on Grifols from $7.60 to $10.30 and gave the company a "neutral" rating in a research note on Tuesday, June 17th. Wall Street Zen raised Grifols from a "buy" rating to a "strong-buy" rating in a research note on Monday.

Grifols Trading Up 0.2%

The company has a debt-to-equity ratio of 1.13, a quick ratio of 0.97 and a current ratio of 2.60. The firm has a market cap of $6.71 billion, a price-to-earnings ratio of 8.35, a price-to-earnings-growth ratio of 0.34 and a beta of 0.55. The company has a 50 day moving average price of $8.42 and a 200 day moving average price of $7.75.

Institutional Trading of Grifols

A number of institutional investors have recently modified their holdings of the company. Goldman Sachs Group Inc. grew its holdings in shares of Grifols by 1.9% during the first quarter. Goldman Sachs Group Inc. now owns 4,212,032 shares of the biotechnology company's stock valued at $29,948,000 after purchasing an additional 80,507 shares during the last quarter. Cubist Systematic Strategies LLC bought a new position in Grifols during the first quarter valued at about $184,000. Royal Bank of Canada grew its holdings in shares of Grifols by 21.7% during the 1st quarter. Royal Bank of Canada now owns 486,824 shares of the biotechnology company's stock worth $3,461,000 after purchasing an additional 86,768 shares in the last quarter. Vident Advisory LLC boosted its holdings in Grifols by 134.5% during the first quarter. Vident Advisory LLC now owns 69,564 shares of the biotechnology company's stock valued at $495,000 after purchasing an additional 39,902 shares in the last quarter. Finally, Groupe la Francaise bought a new position in Grifols in the 1st quarter worth approximately $1,699,000.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.